Trending...
- Velvet Realism Declared a New Genre of Music, Founded by House of Buneau - 137
- One Drop Inspired Reggae Album & E-Book "You Got The Key" Delivers Message of Inner Power & Purpose - 115
- Governor Newsom announces free entry to California State Parks on MLK Day — as Trump swaps the "free day" for his birthday and whitewashes civil rights history from National Parks
Download
Overview of the TCRm-AFP/HLA-A*02 complex with the heavy and light chains of the TCRm (Graphic: Business Wire)
EMERYVILLE, Calif.--(BUSINESS WIRE)--Eureka Therapeutics, Inc., a clinical-stage biotechnology company developing novel T cell therapies to treat solid tumors, today announced the publication of a study in Nature's Scientific Reports entitled "Validation and promise of a TCR mimic antibody for cancer immunotherapy of hepatocellular carcinoma". The study was led by Dr. Cheng Liu, President and Chief Executive Officer of Eureka, Dr. Brian M. Baker and Dr. Moumita Dasgupta of the University of Notre Dame, and Dr. Chang Liu of The First Affiliated Hospital of Xi'an Jiaotong University.
T cell receptor mimic (TCRm) antibodies represent a novel approach to address one of the limitations of immunotherapy. Whereas traditional therapeutics antibodies are limited to targeting cell surface antigens, TCRm antibodies can target intracellular antigens presented by cell surface major histocompatibility complex (MHC) proteins, which enables the targeting of otherwise undruggable cancer antigens.
More on The Californer
Alpha-fetoprotein (AFP) is an intracellular antigen found in hepatocellular carcinoma (HCC), the predominant type of liver cancer. In a previous study, Eureka reported that an engineered TCRm targeting alpha-fetoprotein (AFP)-MHC complex can effectively redirect CAR-T cells against liver cancer cells.
In this study, the crystal structure showed the AFP-MHC targeting TCRm antibody binding directly over the center of the HLA protein. Unlike natural TCRs, the TCRm antibody interfaced with the AFP/HLA-A*02 complex by engaging the AFP peptide along its entire length, contacting most of the amino acids and interacting rigidly with the target complex. The significant interactions with the peptide likely confers the high affinity and specificity of the TCRm to AFP/HLA-A*02 observed in vitro and in animal studies when compared to natural TCRs. Moreover, no off-target effects were observed in the pre-clinical studies.
"TCR mimic antibodies represent a novel way to target the subset of cancer antigens found intracellularly," said Dr. Brian M. Baker, Coleman Professor of Life Sciences at the University of Notre Dame. "The details seen in the structural and biochemical data and the resulting high specificity and affinity for this TCRm could address some of the previous safety concerns about non-specific or off-target recognition in humans."
Eureka fused the binding domain of the TCRm to the γ and δ subunits of a TCR, and co-expressed a co-stimulatory molecule to create its proprietary ARTEMIS® T cell receptor. The engineered T cells showed potent killing activity against AFP-positive cancer cell lines in vitro and in vivo, with no off-target reactivity observed.
A first-in-human safety assessment of anti-AFP targeting ARTEMIS® T cells was conducted over a 17-month period on 6 HCC patients at the First Affiliated Hospital of Xi'an Jiaotong University in China. The anti-AFP targeting ARTEMIS® T cells demonstrated a favorable safety profile with no significant treatment-related adverse events. T cell expansion after infusions and a commensurate drop in serum AFP were detected in most patients in this study.
Eureka is currently conducting two clinical trials (ARYA-1 and ARYA-2) in the United States targeting AFP in patients with liver cancer using TCRm antibodies engineered onto ARTEMIS® T cells (ET140203). A third trial (ARYA-3) targets the GPC3 protein, also found on liver cancer cells, with ARTEMIS® T cells (ECT204). All three trials were granted Orphan Drug Designation by the U.S. Food and Drug Administration. For more information, visit www.eurekaconnectme.com.
More on The Californer
ABOUT EUREKA THERAPEUTICS, INC.
Eureka Therapeutics, Inc. is a privately held clinical-stage biotechnology company focused on developing novel T cell therapies to treat cancers. Its core technology centers around its proprietary ARTEMIS® cell receptor platform and E-ALPHA® antibody discovery platform for the discovery and development of potentially safer and more effective T cell therapies for the treatment of solid tumors and hematologic malignancies. The company currently has two clinical programs, ET140203 (ARYA1 (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT04502082&esheet=52799760&newsitemid=20220803005138&lan=en-US&anchor=ARYA1&index=8&md5=0a67d8c449710f0678a5b1dd8911b95f) for adults and ARYA2 (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT04634357&esheet=52799760&newsitemid=20220803005138&lan=en-US&anchor=ARYA2&index=9&md5=200f387d28667f70d501dbae92acdde9) for pediatrics) and ECT204 (ARYA3 (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT04864054&esheet=52799760&newsitemid=20220803005138&lan=en-US&anchor=ARYA3&index=10&md5=e2bbd769d5ff956241135bda81bee576)), in Phase I/II US trials in patients with advanced liver cancer.
Eureka Therapeutics, Inc. is headquartered in the San Francisco Bay Area. For more information on Eureka, please visit www.eurekatherapeutics.com (https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.eurekatherapeutics.com&esheet=52799760&newsitemid=20220803005138&lan=en-US&anchor=www.eurekatherapeutics.com&index=11&md5=a2baafafa8030a06973651d53156975d).
Contacts
Eureka Therapeutics, Inc.
Natalie Liu
Investor Relations
510-318-9215
IR@eurekainc.com
0) { // Create container for hi-res image jQuery('#bw-release-hires').append('
'); }; }); ]]>
Social Media Profiles
Contacts
Eureka Therapeutics, Inc.
Natalie Liu
Investor Relations
510-318-9215
IR@eurekainc.com
Overview of the TCRm-AFP/HLA-A*02 complex with the heavy and light chains of the TCRm (Graphic: Business Wire)
- Overview of the TCRm-AFP/HLA-A*02 complex with the heavy and light chains of the TCRm (Graphic: Business Wire)
EMERYVILLE, Calif.--(BUSINESS WIRE)--Eureka Therapeutics, Inc., a clinical-stage biotechnology company developing novel T cell therapies to treat solid tumors, today announced the publication of a study in Nature's Scientific Reports entitled "Validation and promise of a TCR mimic antibody for cancer immunotherapy of hepatocellular carcinoma". The study was led by Dr. Cheng Liu, President and Chief Executive Officer of Eureka, Dr. Brian M. Baker and Dr. Moumita Dasgupta of the University of Notre Dame, and Dr. Chang Liu of The First Affiliated Hospital of Xi'an Jiaotong University.
T cell receptor mimic (TCRm) antibodies represent a novel approach to address one of the limitations of immunotherapy. Whereas traditional therapeutics antibodies are limited to targeting cell surface antigens, TCRm antibodies can target intracellular antigens presented by cell surface major histocompatibility complex (MHC) proteins, which enables the targeting of otherwise undruggable cancer antigens.
More on The Californer
- Attention Business, Marketing and Advertising: Is an 8 Million Dollar ad in the Super Bowl worth it?
- White Glove Restoration Expands Rapid-Response Property Damage Restoration Services Across San Diego County
- NOW OPEN - New Single Family Home Community in Manalapan
- Kintetsu And Oversee Announce New Partnership
- Save 10 Percent Off KeysCaribbean's Newly Added Luxury Vacation Home in Marathon
Alpha-fetoprotein (AFP) is an intracellular antigen found in hepatocellular carcinoma (HCC), the predominant type of liver cancer. In a previous study, Eureka reported that an engineered TCRm targeting alpha-fetoprotein (AFP)-MHC complex can effectively redirect CAR-T cells against liver cancer cells.
In this study, the crystal structure showed the AFP-MHC targeting TCRm antibody binding directly over the center of the HLA protein. Unlike natural TCRs, the TCRm antibody interfaced with the AFP/HLA-A*02 complex by engaging the AFP peptide along its entire length, contacting most of the amino acids and interacting rigidly with the target complex. The significant interactions with the peptide likely confers the high affinity and specificity of the TCRm to AFP/HLA-A*02 observed in vitro and in animal studies when compared to natural TCRs. Moreover, no off-target effects were observed in the pre-clinical studies.
"TCR mimic antibodies represent a novel way to target the subset of cancer antigens found intracellularly," said Dr. Brian M. Baker, Coleman Professor of Life Sciences at the University of Notre Dame. "The details seen in the structural and biochemical data and the resulting high specificity and affinity for this TCRm could address some of the previous safety concerns about non-specific or off-target recognition in humans."
Eureka fused the binding domain of the TCRm to the γ and δ subunits of a TCR, and co-expressed a co-stimulatory molecule to create its proprietary ARTEMIS® T cell receptor. The engineered T cells showed potent killing activity against AFP-positive cancer cell lines in vitro and in vivo, with no off-target reactivity observed.
A first-in-human safety assessment of anti-AFP targeting ARTEMIS® T cells was conducted over a 17-month period on 6 HCC patients at the First Affiliated Hospital of Xi'an Jiaotong University in China. The anti-AFP targeting ARTEMIS® T cells demonstrated a favorable safety profile with no significant treatment-related adverse events. T cell expansion after infusions and a commensurate drop in serum AFP were detected in most patients in this study.
Eureka is currently conducting two clinical trials (ARYA-1 and ARYA-2) in the United States targeting AFP in patients with liver cancer using TCRm antibodies engineered onto ARTEMIS® T cells (ET140203). A third trial (ARYA-3) targets the GPC3 protein, also found on liver cancer cells, with ARTEMIS® T cells (ECT204). All three trials were granted Orphan Drug Designation by the U.S. Food and Drug Administration. For more information, visit www.eurekaconnectme.com.
More on The Californer
- Why 'Instant-Liquidity' Gaming is Dominating the Nordic Tech Demographic
- 2026 Historic Art Honor for Candace Chambers-Belida!
- STATEMENT: Shincheonji on Religious Freedom Controversy
- Britt Michaelian and Josh Pierce Pioneer First-Ever Digital Frequency Art and Wellness Experience
- Cyntexa Outlines a Principles-first Approach to Modern Enterprise Transformation
ABOUT EUREKA THERAPEUTICS, INC.
Eureka Therapeutics, Inc. is a privately held clinical-stage biotechnology company focused on developing novel T cell therapies to treat cancers. Its core technology centers around its proprietary ARTEMIS® cell receptor platform and E-ALPHA® antibody discovery platform for the discovery and development of potentially safer and more effective T cell therapies for the treatment of solid tumors and hematologic malignancies. The company currently has two clinical programs, ET140203 (ARYA1 (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT04502082&esheet=52799760&newsitemid=20220803005138&lan=en-US&anchor=ARYA1&index=8&md5=0a67d8c449710f0678a5b1dd8911b95f) for adults and ARYA2 (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT04634357&esheet=52799760&newsitemid=20220803005138&lan=en-US&anchor=ARYA2&index=9&md5=200f387d28667f70d501dbae92acdde9) for pediatrics) and ECT204 (ARYA3 (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT04864054&esheet=52799760&newsitemid=20220803005138&lan=en-US&anchor=ARYA3&index=10&md5=e2bbd769d5ff956241135bda81bee576)), in Phase I/II US trials in patients with advanced liver cancer.
Eureka Therapeutics, Inc. is headquartered in the San Francisco Bay Area. For more information on Eureka, please visit www.eurekatherapeutics.com (https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.eurekatherapeutics.com&esheet=52799760&newsitemid=20220803005138&lan=en-US&anchor=www.eurekatherapeutics.com&index=11&md5=a2baafafa8030a06973651d53156975d).
Contacts
Eureka Therapeutics, Inc.
Natalie Liu
Investor Relations
510-318-9215
IR@eurekainc.com
0) { // Create container for hi-res image jQuery('#bw-release-hires').append('
'); }; }); ]]>
Social Media Profiles
- Eureka Therapeutics (https://www.facebook.com/eurekatherapeutics)
- Eureka Therapeutics (https://twitter.com/EurekaThera)
- Eureka Therapeutics (https://www.linkedin.com/company/497678)
Contacts
Eureka Therapeutics, Inc.
Natalie Liu
Investor Relations
510-318-9215
IR@eurekainc.com
Filed Under: Business
0 Comments
Latest on The Californer
- California: Protected: FRAUD ALERT: Newsom adds new list of Trump's pardoned fraudster friends to Trump Criminals tracker
- Fashion Meets Philanthropy at Ralph Lauren Palm Desert
- Long Beach: Spring Recreation Classes Open for Registration February 2
- International Cat Caregivers Day Launches February 4 During National Cat Health Month
- FeedSocially - Post Once, Publish Everywhere
- Closed Systems That Crown Winners, Silence Accountability, And Endanger Lives — From Bodybuilding to Boeing
- At World Economic Forum, Governor Newsom announces California shattered clean car goal, surpassing 2.5M ZEV sales despite Trump's chaos
- James D. Harding Promoted to Century Fasteners Corp. – Managing Director
- Finland's New Gambling Watchdog Handed Sweeping Powers to Revoke Licenses and Block Illegal Casino Sites
- Powering the AI, Defense and Aerospace Future with Energy Infrastructure and Digital Asset Strength: KULR Technology Group, Inc. $KULR
- $10 Price Target in Think Equity Report Supported by Inventory Financing Floorplan Boot to $60 Million for 2026 Sales Growth in Pre-Owned Boats: $OTH
- Poolvillas Expands Local Presence on the Costa Blanca with New Offices in Moraira and Denia – Over 30 Years of Expertise Now Even Closer to Guests
- Governor Newsom announces first-in-the-nation privacy tool allowing Californians to block the sale of their data
- West Hive Capital Sells So Cal Retail Center for $24.5 Million
- Rentail.space Launches AI-Powered Marketplace Connecting Merchants with Short-Term Retail Spaces
- Radarsign Redefines Crosswalk Safety with Launch of CrossCommand™ RRFB Crosswalk
- OpenSSL Corporation Opens 2026 Advisory Committees' Elections: Shape the Future!
- Steve Everett Jr. Named President of L.T. Hampel Corporation
- Acuvance Acquires ROI Healthcare Solutions, Building a Dedicated Healthcare ERP Practice
- Max Tucci Award-Winning Media Powerhouse Launches New Podcast —Executive Produced by Emmy-Winning Daytime Icons Suzanne Bass & Fran Brescia Coniglio